

ASX Announcement

16 April 2024

First Turkish patient treated with OncoSil™ device

This first treatment in Türkiye comes soon after EDH Nuclear Medicine & Healthcare

Services was appointed as OncoSil Medical's distributor in Türkiye

Key Highlights

- ✓ The first patient treatment utilising the OncoSil™ device occurred in Türkiye on 15 April.
- ✓ This treatment was undertaken at the Istanbul Memorial Hospital.
- ✓ The treatment comes less than three months after EDH Nuclear Medicine & Healthcare Services was appointed as OncoSil Medical's distributor in Turkey.

Sydney, Australia – 16 April 2024: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce the first treatment utilising the OncoSil™ device on a patient residing in Türkiye occurred on 15 April 2024. This treatment was undertaken at the Istanbul Memorial Hospital.

The OncoSil™ device achieves first treatment in the Turkish market

The first treatment utilising the OncoSil™ device that involved a patient residing in Türkiye occurred at the Istanbul Memorial Hospital on 15 April 2024.

This hospital was founded in February 2000 with the goal of becoming a world-class healthcare brand with distinguished staff and satisfaction-oriented international quality standards by making a difference with pioneering procedures based on ethical principles.

OncoSil Medical CEO & Managing Director Nigel Lange, said: *“We are delighted to see the delivery of another milestone in our strategy to penetrate the large and potentially lucrative European market. The just completed treatment at Istanbul Memorial Hospital represents a further expansion in the geographic footprint for our revolutionary OncoSil™ device. This achievement would not have been possible without the assistance of our recently appointed Turkish distributor, EDH Nuclear Medicine & Healthcare Services. Less than three months after coming on board, they have helped us deliver the first treatment on a Turkish-domiciled patient utilising the OncoSil™ device.”*

Istanbul Memorial Hospital Nuclear Medicine Physician Professor Cuneyt Turkmen, said: *“We are thrilled to be part of the OncoSil™ device’s ongoing validation and early commercialisation strategies. Given the current poor prognosis for long-term survival for patients with locally advanced pancreatic cancer, it will truly be an exciting development if the OncoSil™ device proves to be a more effective treatment option for patients with this type of cancer.”*

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 16096424981</p>	<p>Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699</p>
--	--	--

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References:

1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>

About Memorial Hospitals Istanbul

Memorial Hospitals Istanbul, Türkiye was founded in February 2000 with the goal of becoming a world-class healthcare brand with distinguished staff and satisfaction-oriented international quality standards by making a difference with pioneering procedures based on ethical principles. Memorial is the first hospital in Türkiye to receive a JCI (Joint Commission International) accreditation certificate, and the 21st in the world, bringing world-class quality healthcare to Turkey.

With its specialist physicians, healthcare staff who combine their knowledge and experience with tender care for patients, its patient-centred service approach, quality policy, diagnosis and treatment facilities equipped with advanced medical technology, modern spaces, and comfortable patient rooms, Memorial is the home of trust in healthcare.

Memorial is known for departments like IVF, Genetics, Cardiovascular Surgery, Organ Transplantation, Oncology, Neurosurgery, Orthopedics and Traumatology, and Eye Diseases, and is a reference centre in branches like other Surgical Sciences, Cardio Health, Women’s Health, Children’s Health, Robotic Surgery, Stroke, and Bone Marrow Transplant.